CL2024000776A1 - Milvexian para la prevención y el tratamiento de trastornos tromboembólicos - Google Patents

Milvexian para la prevención y el tratamiento de trastornos tromboembólicos

Info

Publication number
CL2024000776A1
CL2024000776A1 CL2024000776A CL2024000776A CL2024000776A1 CL 2024000776 A1 CL2024000776 A1 CL 2024000776A1 CL 2024000776 A CL2024000776 A CL 2024000776A CL 2024000776 A CL2024000776 A CL 2024000776A CL 2024000776 A1 CL2024000776 A1 CL 2024000776A1
Authority
CL
Chile
Prior art keywords
milvexian
prevention
treatment
thromboembolic disorders
disorders
Prior art date
Application number
CL2024000776A
Other languages
English (en)
Spanish (es)
Inventor
M Luettgen Joseph
Strony John
Peters Gary
Chintala Madhu
Nessel Christopher
Vidya Perera Liyanage
Li Danshi
Alfred Seiffert Dietmar
Jones-Burton Charlotte
Original Assignee
Bristol Myers Squibb Co
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Janssen Pharmaceutica Nv filed Critical Bristol Myers Squibb Co
Publication of CL2024000776A1 publication Critical patent/CL2024000776A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024000776A 2021-09-17 2024-03-15 Milvexian para la prevención y el tratamiento de trastornos tromboembólicos CL2024000776A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163245522P 2021-09-17 2021-09-17
US202163278582P 2021-11-12 2021-11-12

Publications (1)

Publication Number Publication Date
CL2024000776A1 true CL2024000776A1 (es) 2024-07-26

Family

ID=83688923

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024000776A CL2024000776A1 (es) 2021-09-17 2024-03-15 Milvexian para la prevención y el tratamiento de trastornos tromboembólicos

Country Status (11)

Country Link
US (1) US20250099466A1 (cg-RX-API-DMAC7.html)
EP (1) EP4401736A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024534427A (cg-RX-API-DMAC7.html)
KR (1) KR20240060820A (cg-RX-API-DMAC7.html)
AU (1) AU2022345862A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232633A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000776A1 (cg-RX-API-DMAC7.html)
IL (1) IL310894A (cg-RX-API-DMAC7.html)
MX (1) MX2024002857A (cg-RX-API-DMAC7.html)
TW (1) TW202327607A (cg-RX-API-DMAC7.html)
WO (1) WO2023043999A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4565231A1 (en) * 2022-08-01 2025-06-11 Bristol-Myers Squibb Company Use of milvexian for treating or preventing ischemic stroke
CN121001727A (zh) * 2023-04-19 2025-11-21 百时美施贵宝公司 米尔维仙(milvexian)于治疗及预防患有心血管或脑血管疾病的患者的血栓病况的用途
CN121443289A (zh) * 2023-04-19 2026-01-30 百时美施贵宝公司 米尔维仙在治疗或预防患有急性冠状动脉综合征的患者的不良脑血管事件或不良心血管事件中的用途
CN121398811A (zh) * 2023-04-19 2026-01-23 百时美施贵宝公司 米尔维仙于治疗及预防患有心房颤动的患者的血栓病况的用途
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof
WO2026115567A1 (en) * 2024-11-26 2026-06-04 Dr. Reddy’S Laboratories Limited Sustained release formulations of milvexian

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
KR20210151183A (ko) 2019-04-11 2021-12-13 브리스톨-마이어스 스큅 컴퍼니 치료 혈장 농도를 달성하기 위한 무정형 고체 및 가용화된 제제의 증진된 성능

Also Published As

Publication number Publication date
US20250099466A1 (en) 2025-03-27
JP2024534427A (ja) 2024-09-20
KR20240060820A (ko) 2024-05-08
TW202327607A (zh) 2023-07-16
CA3232633A1 (en) 2023-03-23
AU2022345862A1 (en) 2024-03-14
MX2024002857A (es) 2024-03-21
IL310894A (en) 2024-04-01
WO2023043999A1 (en) 2023-03-23
EP4401736A1 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
MX2024002857A (es) Milvexian para la prevencion y el tratamiento de trastornos tromboembolicos.
JOP20220263A1 (ar) مثبط ret بلوري
CL2022003348A1 (es) Composiciones y métodos para el tratamiento del síndrome de dificultad respiratoria aguda y trastornos inflamatorios
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
MX2025004367A (es) Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2021010193A (es) Azepino-indoles y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
CY1122867T1 (el) Συνθεσεις που περιλαμβανουν ενα βακτηριακο στελεχος του blautia hydrogenotrophica για χρηση στην θεραπεια ή προληψη διαρροιας ή δυσκοιλιοτητας
UY37554A (es) (aza)indol- y benzofuran-3-sulfonamidas
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
MX2019003703A (es) Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
MX2020009942A (es) Compuestos y usos de los mismos.
CO2024009571A2 (es) Inhibidores de parp1
MX2019008124A (es) Metodos para el tratamiento de trastornos neurologicos.
UY38352A (es) Inhibidores de integrina alfavbeta6
CO2018013020A2 (es) Combinaciones farmacéuticas para el tratamiento del cáncer
CL2020001888A1 (es) Terapia de combinación para tratar o prevenir el cáncer.
MX2020008456A (es) Uso de tradipitant para tratar la cinetosis.
PH12019502315A1 (en) Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
MX2019010060A (es) Composiciones y metodo para tratar cancer.
MX2023002851A (es) Tratamiento de la enfermedad de parkinson.
EP4556072A3 (en) Compositions for monocyte and macrophage polarization and methods of use
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.